SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing a significant surge in momentum as the community anticipates groundbreaking clinical data for pancreatic and brain cancer treatments scheduled for presentation at major medical conferences. Investors are actively discussing the stock's transition into a catalyst-heavy phase, with enthusiasm fueled by favorable interim study results and recent analyst price target upgrades.

Inter & Co., Inc. Is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Banking, Securities, Insurance Brokerage, Marketplace, Asset Management, Service, and Other. The Banking segment offers checking accounts cards, deposits, loans and advances, and other services through mobile application. The Securities segment is involved in the acquisition, sale and custody of securities, the structuring and distribution of securities in the capital market, and the provision of administration services to investment funds. The Insurance Brokerage segment includes insurance products underwritten by insurance companies, such as warranties, life, property and automobile insurance, and pension products, as well as consortium products provided by a third party. The Marketplace segment operates a digital platform, which offers goods and services to its customers. The Asset Management segment is composed of the operations related to the management of fund portfolios and other assets. The Service segment consists of collection and management of personal information, development and licensing of customized computer programs, development and licensing of non-customized computer programs and technical support, maintenance, and other information technology services. The company was founded on January 26, 2021 and is headquartered in Belo Horizonte, Brazil.

Inter & Co Inc - Ordinary Shares - Class A

INTER  CO INC

Inter & Co is capturing investor attention as it expands its AI-powered super app strategy and targets record growth, leading many in the community to view the stock as undervalued despite recent price volatility. While some participants are wary of macroeconomic headwinds, bulls are actively discussing the company's strong client acquisition and long-term potential, with many advocating for buying into current support levels.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased trading activity as market participants digest a significant portfolio shake-up involving Berkshire Hathaway's full exit from the stock, which many community members view as a misplaced move following the company's recent strong performance and solid fundamentals. Traders are actively debating the stock's future trajectory, with many dismissing the recent price dip as an overreaction and identifying it as a buying opportunity in a defensive leader poised for continued growth.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is attracting attention as it secures a significant purchase order for its SiCore silicon-anode batteries to power electric two and three-wheelers in the Chinese market. The community is actively debating the company's long-term growth potential and manufacturing strategy, with many monitoring whether warrant exchange activities and short interest levels will act as catalysts for future price movement.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently facing significant selling pressure as Treasury yields climb toward 5%, driven by intensifying inflation fears tied to the ongoing conflict in the Middle East and rising energy costs. Market participants are actively discussing the possibility of a debt-driven volatility spike, with many investors hedging against further downside through heavy put option activity while debating whether this represents a long-term bottom or the start of a deeper bond market rout.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors weigh strong demand for its AI-focused high-speed networking gear against concerns over potential margin pressures from industry-wide supply chain constraints. The community is actively debating the stock's long-term potential as a critical AI infrastructure provider, often comparing its recent volatility to other sector leaders like Cisco while highlighting institutional analyst upgrades.

Alpha Pro Tech Ltd. engages in the business of protecting people, products and environment. It develops, manufactures and markets disposable and limited use protective apparel products for the industries, clean room, medical and dental markets. The company operates through the Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment includes many different styles of disposable products, such as shoe covers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. The Building Supply segment consists of a line of construction supply weatherization products, namely house wrap and synthetic roof underlayment. The company was founded in 1983 and is headquartered in Aurora, Canada.

Alpha Pro Tech Ltd.

Alpha Pro Tech is seeing renewed market interest driven by recent news headlines regarding respiratory viruses, causing traders to revisit the stock as a potential protective equipment play. The community is actively debating the stock's valuation relative to its tangible book value, with some seeing a bargain while others express skepticism over the lack of sustained growth catalysts outside of pandemic-related spikes.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the announcement of an exclusive supply agreement for the Tokyo-172 strain of BCG, a development investors hope will resolve long-standing U.S. supply shortages and bolster the commercial rollout of Anktiva. Community sentiment remains focused on the companys ongoing participation in the American Urological Association annual meeting, with many long-term shareholders anticipating that resolving supply bottlenecks and recent leadership changes at the FDA will accelerate clinical progress and alleviate short-selling pressure.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense volatility as investors weigh a major institutional funding round at a premium against ongoing concerns over valuation and short-selling campaigns. The community remains sharply divided, with bulls pointing to the company's new AI networking partnerships as validation, while bears continue to scrutinize the company's operational transparency and recent share issuance.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as the community closely monitors the impending 80th clinical trial event for its lead asset, GPS, while institutional buying momentum intensifies following recent 13F filings. Investors are actively discussing the potential for a transformative breakthrough in AML therapies, with many highlighting the stock's significant long-term potential as it nears critical data readouts and institutional ownership increases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AdvanSix Q1 Earnings Call Highlights

AdvanSix Announces First Quarter 2026 Financial Results

AdvanSix (NYSE: ASIX), a vertically integrated chemistry company serving diverse end markets, today announced its financial results for the first quarter ending March 31, 2026. Overall, the Company...

AdvanSix Announces Process Design and License Agreement to Assess Expansion of Its Ammonia Platform to Supply Growing Regional Diesel Exhaust Fluid Market

AdvanSix (NYSE: ASIX), a vertically integrated chemistry company serving diverse end markets, today announced it has entered into a process design and licensing agreement to assess expansion of its...

AdvanSix (NYSE:ASIX) Hits New 12-Month High  - Still a Buy?

AdvanSix (NYSE:ASIX) Reaches New 12-Month High - Time to Buy...

AdvanSix (ASIX) Projected to Post Quarterly Earnings on Friday

AdvanSix (NYSE:ASIX) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-advansix-inc-stock...

Waterfront Wealth Inc. Acquires 53,261 Shares of AdvanSix $ASIX

Waterfront Wealth Inc. increased its holdings in AdvanSix (NYSE:ASIX - Free Report) by 380.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,250 shares of the company's stock after buying an addition...

AdvanSix (NYSE:ASIX)  Shares Down 8.8%   - Here's Why

AdvanSix (NYSE:ASIX) Trading Down 8.8% - Time to Sell...

AdvanSix to Release First Quarter Financial Results and Hold Investor Conference Call on May 8

AdvanSix (NYSE: ASIX), an integrated chemistry company serving diverse end markets, will issue its first quarter 2026 financial results before the opening of the New York Stock Exchange on Friday...

Short Interest in AdvanSix (NYSE:ASIX) Drops By 19.0%

AdvanSix (NYSE:ASIX - Get Free Report) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 631,964 shares, a decrease of 19.0% from the...

AdvanSix Appoints Patrick C. Day as Senior Vice President and Chief Financial Officer

AdvanSix (NYSE: ASIX), an integrated chemistry company serving diverse end markets, today announced the appointment of Patrick C. Day as its Senior Vice President and Chief Financial Officer, effective April 27, 2026. Pat will report directly to Erin Kane, President and Chief Executive Officer of...

Advansix, Inc. engages in the business of building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The firm’s products include nylon resin, caprolactam, ammonium sulfate fertilizer, and chemical intermediates. It offers products to the carpet, engineering plastic, food packaging, building and construction, composites, plant nutrition, paints, and coating markets. The company was founded on May 4, 2016 and is headquartered in Parsippany, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.56	--	--	N/A
Q1 '26	-$0.47	-$0.50	-5.26%	MISSED
Q4 '25	-$0.06	$0.03	150.00%	BEAT
Q3 '25	$0.40	$0.08	-80.00%	MISSED
Q2 '25	$1.18	$1.24	4.64%	BEAT

ASIX
AdvanSix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest ASIX News

ASIXAdvanSix Inc